• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Is Oral Fluconazole Use During the First Trimester Linked to Congenital Malformations?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Fluconazole is commonly used to treat vulvovaginal candidiasis
    • FDA cautions against use in pregnancy due to concern regarding birth defects and potential risk for stillbirth or miscarriage
  • Teratogenicity studies on the use of fluconazole in humans have been inconsistent
  • Zhu et al. (BMJ, 2020) assessed the risk of congenital malformations associated with exposure to commonly used doses of oral fluconazole in the first trimester of pregnancy

METHODS:

  • Population based cohort study
  • Data source
    • The US nationwide Medicaid Analytic eXtract (MAX) 2000 to 2014 (most current data at time of this study)
  • Participants
    • Pregnant women ages 12 to 55
    • Enrolled in Medicaid from ≥3 months before the DLMP until 1 month after delivery
    • Infants enrolled for three or more months after birth
  • Interventions
    • Use of fluconazole or topical azoles: ≥1 prescriptions during the first trimester of pregnancy
    • Topical azoles (e.g. butoconazole, clotrimazole, miconazole, terconazole, tioconazole, and nystatin) used as primary reference group to minimize confounding based on indication
  • Diagnoses made during the first 90 days post delivery
  • Primary outcome
    • Risks for the following birth defects associated with fluconazole exposure
      • Musculoskeletal malformations
      • Conotruncal malformations
      • Oral clefts

RESULTS:

  • 1,969,954 pregnancies included
    • Exposed to oral fluconazole during first trimester: 1.9%
    • Exposed to topical azoles: 4.2%

Absolute Risks with Fluconazole Versus Topical Azoles

  • Musculoskeletal malformations
    • 52.1 (95% CI, 44.8 to 59.3) vs 37.3 (95% CI, 33.1 to 41.4) per 10,000 pregnancies
  • Conotruncal malformations
    • 9.6 (95% CI, 6.4 to 12.7) vs 8.3 (95% CI, 6.3 to 10.3) per 10,000 pregnancies
  • Oral clefts
    • 9.3 (95% CI, 6.2 to 12.4) versus 10.6 (95% CI, 8.4 to 12.8) per 10,000 pregnancies

Adjusted Relative Risks

  • Musculoskeletal malformations: 1.30 (95% CI, 1.09 to 1.56)
  • Conotruncal malformations: 1.04 (95% CI, 0.70 to 1.55)
  • Oral clefts: 0.91 (95% CI, 0.61 to 1.35)

Adjusted Relative Risks Based on Cumulative Doses of Fluconazole

  • 150 mg
    • Musculoskeletal malformations: 1.29 (95% CI,1.05 to 1.58)
    • Conotruncal malformations: 1.12 (95% CI, 0.71 to 1.77)
    • Oral clefts: 0.88 (95% CI, 0.55 to 1.40)
  • 150 mg to 450 mg
    • Musculoskeletal malformations: 1.24 (95% CI, 0.93 to 1.66)
    • Conotruncal malformations: 0.61 (95% CI, 0.26 to 1.39)
    • Oral clefts: 1.08 (95% CI, 0.58 to 2.04)
  • >450 mg
    • Musculoskeletal malformations: 1.98 (95% CI, 1.23 to 3.17)
    • Conotruncal malformations: 2.30 (95% CI, 0.93 to 5.65)
    • Oral clefts: and 0.94 (95% CI, 0.23 to 3.82)

CONCLUSION:

  • Use of oral fluconazole during the first trimester was not associated with oral clefts or conotruncal malformations but was associated with an increased risk for musculoskeletal malformations

Learn More – Primary Sources:

Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Diagnosis and Treatment of Vulvovaginal Candidiasis
Oral Fluconazole Exposure in Pregnancy and Associated Risks for Adverse Events
Oral Fluconazole in First Trimester and Adverse Outcomes
Is Oral Fluconazole Use in Pregnancy Linked to Stillbirths?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site